Clinical Guidelines

Building Better Oral Suspensions for Pediatric & Real-World Use

Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation

  • By

  • February 18, 2026

  • 6 min

Share

  • 1

    Greg Thomas leads R&D at Kiel Laboratories.

  • 2

    Focuses on therapies for underserved populations.

  • 3

    Vyscoxa project aimed to provide a liquid dosage form for children.

  • 4

    Challenges include palatability and stability in formulations.

  • 5

    Importance of digital fluency and collaboration for future formulation scientists.

Original Source(s)

Building Better Oral Suspensions for Pediatric & Real-World Use

Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation

  • February 18, 2026

  • 6 min

Related Content

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

Rethinking Acetaminophen in the NICU

Prophylactic treatment closed the ductus arteriosus faster but did not reduce mortality or severe morbidity in extremely premature infants

Omadacycline for Pediatric CAP

Case details intravenous-to-oral strategy after multiple antibiotic hypersensitivity reactions